Fig. 3From: Continual reassessment method for dose escalation clinical trials in oncology: a comparison of prior skeleton approaches using AZD3514 dataFinal dose toxicity curves and 95 % prediction intervals for every CRM method. The predicted probabilities of experiencing a DLT and corresponding 95 % prediction intervals for each prior skeleton approach used in the extended CRM method after the MTD has been determined for the AZD3514 dataBack to article page